advertisement
Advances in Therapy 25
Showing records 1 to 25 |
Display all abstracts in Advances in Therapy69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsQuaranta L
Advances in Therapy 2016; 33: 1305-1315
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical TherapySato S
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial CellsNakano T
Advances in Therapy 2016; 33: 1452-1459
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER StudyKawase K
Advances in Therapy 2016; 33: 1612-1627
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical TherapyHirooka K
Advances in Therapy 2016; 33: 1628-1634
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER StudyVittitow JL
Advances in Therapy 2016; 33: 1612-1627
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial CellsInoue R
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsBiagioli E
Advances in Therapy 2016; 33: 1305-1315
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical TherapyNitta E
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial CellsKimura T
Advances in Therapy 2016; 33: 1452-1459
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER StudyWeinreb RN
Advances in Therapy 2016; 33: 1612-1627
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsGalli F
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial CellsSuzumura H
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsPoli D
Advances in Therapy 2016; 33: 1305-1315
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER StudyAraie M
Advances in Therapy 2016; 33: 1612-1627
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical TherapyUkegawa K
Advances in Therapy 2016; 33: 1628-1634
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial CellsTanino T
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsRulli E
Advances in Therapy 2016; 33: 1305-1315
69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study Advances in Therapy 2016; 33: 1612-1627
69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical TherapyTsujikawa A
Advances in Therapy 2016; 33: 1628-1634
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsRiva I
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial CellsYamazaki Y
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsHollander L
Advances in Therapy 2016; 33: 1305-1315
69287 Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial CellsYoshikawa K; Tatemichi M
Advances in Therapy 2016; 33: 1452-1459
69177 Latanoprost and Dorzolamide for the Treatment of Pediatric Glaucoma: The Glaucoma Italian Pediatric Study (Gipsy), Design and Baseline CharacteristicsKatsanos A; Longo A; Uva MG; Torri V; Weinreb RN
Advances in Therapy 2016; 33: 1305-1315
Issue 18-1
Change Issue
advertisement